Literature DB >> 15249541

Comparison of HLA-DR1-restricted T cell response induced in HLA-DR1 transgenic mice deficient for murine MHC class II and HLA-DR1 transgenic mice expressing endogenous murine MHC class II molecules.

Anthony Pajot1, Véronique Pancré, Nicolas Fazilleau, Marie-Louise Michel, Gerhild Angyalosi, David M Ojcius, Claude Auriault, François A Lemonnier, Yu-Chun Lone.   

Abstract

Transgenic mice expressing human HLA class II molecules provide a useful model for identifying HLA-restricted CD4+ epitopes. However, the influence of endogenous murine H-2-restricted T cell responses on HLA-restricted responses is not known. In the present study, we show that HLA-DR1 transgenic mice deficient for H-2 class II expression (HLA-DR1+/+/IAbeta0/0) exhibit an equivalent expression level of the transgene HLA-DR1 and a similar diversity in the TCR repertoire, but a slightly different number of CD4+ peripheral T cells, when compared to HLA-DR1 transgenic mice in which H-2 class II molecules were retained (HLA-DR1+/+/IAbeta+/+). More importantly, a strong antigen-specific HLA-DR1-restricted response was observed in nearly all HLA-DR1+/+/IAbeta0/0 mice immunized with HBV envelope protein (HBs) or capsid protein (HBc), whereas weak HBs- or HBc-specific HLA-DR1-restricted responses were detected in half of the immunized HLA-DR1+/+/IAbeta+/+ mice. Conversely, strong HBs- or HBc-specific H-2-restricted T cell responses were detected in HLA-DR1+/+/IAbeta+/+ mice but not in HLA-DR1+/+/IAbeta0/0 mice. Our results indicate that the coexpression of endogenous H-2 class II molecules reduces the intensity of HLA-DR1-restricted antigen-specific responses in transgenic mice, by favoring murine over human MHC recognition and education. Thus, HLA-DR1+/+/IAbeta0/0 mice represent a better model for identifying and characterizing HLA-DR1-restricted epitopes relevant for human disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249541     DOI: 10.1093/intimm/dxh129

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  4 in total

1.  Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and Listeria vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming.

Authors:  Laura E Johnson; Dirk Brockstedt; Meredith Leong; Peter Lauer; Erin Theisen; John-Demian Sauer; Douglas G McNeel
Journal:  Oncoimmunology       Date:  2018-05-07       Impact factor: 8.110

2.  Bone loss and aggravated autoimmune arthritis in HLA-DRβ1-bearing humanized mice following oral challenge with Porphyromonas gingivalis.

Authors:  Indra Sandal; Anastasios Karydis; Jiwen Luo; Amanda Prislovsky; Karen B Whittington; Edward F Rosloniec; Chen Dong; Deborah V Novack; Piotr Mydel; Song Guo Zheng; Marko Z Radic; David D Brand
Journal:  Arthritis Res Ther       Date:  2016-10-26       Impact factor: 5.156

3.  Generation of murine tumor cell lines deficient in MHC molecule surface expression using the CRISPR/Cas9 system.

Authors:  Krishna Das; David Eisel; Clarissa Lenkl; Ashish Goyal; Sven Diederichs; Elke Dickes; Wolfram Osen; Stefan B Eichmüller
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

4.  Association between the frequency of class II HLA antigens and the susceptibility to intrauterine infection of hepatitis B virus.

Authors:  Yuan-yong Xu; Ji-yun Yu; Yan-wei Zhong; Hong-bin Song; Hui-hui Liu; Lei-li Jia; Shen-long Li; Jian-qiu Xu; Qiao Li
Journal:  Int J Biol Sci       Date:  2008-04-25       Impact factor: 6.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.